Renal Insufficiency

Top drugs studied for this disease

EMA withdrawal · 2023-12-13
EMA Application withdrawn: Jesduvroq (daprodustat) — GlaxoSmithKline Trading Services Limited
The EMA has withdrawn the marketing authorization application for Jesduvroq (daprodustat) by GlaxoSmithKline Trading Services Limited.
CLINICAL_TRIALS withdrawal · 2014-06-17
Clinical Trial Update: Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction [Phase 1]
A Phase 1 trial evaluating chimeric natriuretic peptide versus placebo in patients with stable heart failure and moderate renal dysfunction …